[HTML] sciencedirect.com

[HTML][HTML] Gemcitabine and rapamycin-loaded mixed polymeric thermogel for metastatic pancreatic cancer therapy

SY Kim, MJ Jo, MS Yoon, CE Jin, YB Shin… - Journal of Controlled …, 2023 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer–related death
and has a poor 5–year overall survival. The superior therapeutic benefits of combination or …
被引用次数：3 相关文章

Gemcitabine and rapamycin-loaded mixed polymeric thermogel for metastatic pancreatic cancer therapy

SY Kim, MJ Jo, MS Yoon, CE Jin… - Journal of …, 2023 - scholarworks.sookmyung.ac.kr
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer–related death
and has a poor 5–year overall survival. The superior therapeutic benefits of combination or …

Gemcitabine and rapamycin-loaded mixed polymeric thermogel for metastatic pancreatic cancer therapy

SY Kim, MJ Jo, MS Yoon, CE Jin, YB Shin… - … Clinics and Research, 2023 - journals.lww.com
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer–related death
and has a poor 5–year overall survival. The superior therapeutic benefits of combination or …

Gemcitabine and rapamycin-loaded mixed polymeric thermogel for metastatic pancreatic cancer therapy.

SY Kim, MJ Jo, MS Yoon, CE Jin, YB Shin… - Journal of Controlled …, 2023 - europepmc.org
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related death
and has a poor 5-year overall survival. The superior therapeutic benefits of combination or …

Gemcitabine and rapamycin-loaded mixed polymeric thermogel for metastatic pancreatic cancer therapy

SY Kim, MJ Jo, MS Yoon, CE Jin, YB Shin… - Journal of controlled … - pubmed.ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related death
and has a poor 5-year overall survival. The superior therapeutic benefits of combination or …